x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:26:53

Integrating New Therapies Into the Management of...

Decera Clinical Education Oncology Podcast ·

2021/08/24

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:Treatment after first relapsedOptimal use of CAR T-cell therapyWhen to use selinexor and belantamab mafodotinCOVID-19 vaccinations for patients with myelomaPresenters:Paul G. Richardson, MDR. J. Corman Professor of MedicineHarvard Medical

en

00:41:28

Expert Insights on Optimal Use of CDK4/6 Inhibitors...

Decera Clinical Education Oncology Podcast ·

2021/08/19

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:How the experts currently use CDK4/6 inhibitors in clinical practiceClinical implications of key studies on CDK4/6 inhibitors from ASCO 2021Strategies for counseling patients receiving CDK4/6 inhibitorsPresenters:Joyce O’Shaughnessy,

en

00:17:08

Essential Biomarker Testing in GI Cancers

Decera Clinical Education Oncology Podcast ·

2021/08/18

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:Current testing approaches, including IHC and PD-L1 assays and next-generation sequencingTumor agnostic testing: MSI, TMB, and NTRK fusion testingColon cancer: RAS, BRAF, and HER2Gastric cancer: PD-L1, HER2, and morePancreatic cancer: BRCABiliary cancers: FGFR and IDH1Liquid biopsiesWhen to testPresenter:John L. Marshall, MDChief, Division of

en

00:08:04

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast...

Decera Clinical Education Oncology Podcast ·

2021/08/05

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:Javier Cortes, MD, PhDHead, Breast Cancer ProgramIOB

en

00:21:58

The Latest Advances and Guidance in Nonmetastatic...

Decera Clinical Education Oncology Podcast ·

2021/07/30

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:Updated safety and patient preference data from the ARAMIS and ODENZA trialsChoice of apalutamide, darolutamide, and enzalutamideCounseling patients on adverse eventsManaging patients with asymptomatic nonmetastatic

en

00:13:13

Managing Serious Adverse Events Associated with BTK...

Decera Clinical Education Oncology Podcast ·

2021/07/27

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:Atrial fibrillationCardiac toxicityMusculoskeletal AEsManaging risk of infectionsPresenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandCE/AAPA credit available by visiting the online

en

00:17:50

Strategies for Avoiding Adverse Reactions to BTK...

Decera Clinical Education Oncology Podcast ·

2021/07/27

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:Patient adherence to oral medicationsLifestyle changesMonitoring, recording, and reporting of AEsThe role of the nurseThe role of the patientAE managementPresenter: Sandra E. Kurtin, PhD, ANP-C, AOCNDirector, Advanced Practice and Clinical IntegrationThe University of Arizona Cancer

en

00:15:08

Strategies for Avoiding Adverse Reactions to BTK...

Decera Clinical Education Oncology Podcast ·

2021/07/27

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:PharmacokineticsDrug metabolismDrug–drug interactionsDrug–food interactionsThe role of CYP enzymesFoods to avoidMedication reviewPresenter:Sandra E. Kurtin, PhD, ANP-C, AOCNDirector, Advanced Practice and Clinical IntegrationThe University of Arizona Cancer CenterAssistant Professor, Clinical

en

00:13:46

BTK Inhibitors in CLL and Lymphomas: Overview and ...

Decera Clinical Education Oncology Podcast ·

2021/07/23

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:Rationale for inhibiting BTKMOA of BTK inhibitorsApproved BTK inhibitorsRecent clinical trial findingsLink to full program, including downloadable slidesets:https://bit.ly/3iwN9UbPresenter: Beth Faiman, PhD, MSN, APRN-BC, AOCNNurse PractitionerCleveland Clinic Taussig Cancer InstituteCleveland, Ohio

en

00:12:30

Adverse Events Associated with BTK Inhibitor Treatment

Decera Clinical Education Oncology Podcast ·

2021/07/23

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:BTK inhibitor selectivityBTK inhibitor adverse event profilesIbrutinib intoleranceManagement of common adverse eventsPresenter:Amy Goodrich, RN, MSN, CRNP-ACResearch Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandCE/AAPA credit available by visiting the online

en

00:21:17

Radiopharmaceuticals in the Treatment of Metastatic...

Decera Clinical Education Oncology Podcast ·

2021/07/20

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trialOngoing trials evaluating radionuclides in combination with

en

00:15:44

How to Integrate Novel Treatment Classes for R/R...

Decera Clinical Education Oncology Podcast ·

2021/07/19

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.Presenter: Donna Catamero, ANP-BC, OCN, CCRCAssociate Director,

en

00:18:02

Expert Answers to HCP Questions on CAR T-Cell Therapy

Decera Clinical Education Oncology Podcast ·

2021/07/19

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:At what time in the treatment journey should CAR T-cell therapy be considered?How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?How is CAR T-cell therapy best used for multiple myeloma?What qualities of bridging therapy are most

en

00:12:53

How to Integrate Novel Treatment Classes for R/R...

Decera Clinical Education Oncology Podcast ·

2021/07/16

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.Presenter: Tiffany Richards,

en

00:13:34

Treatment Options for Patients With Multiple Myeloma...

Decera Clinical Education Oncology Podcast ·

2021/07/14

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:Strategies for monitoring for disease progressionDisease, therapy, and patient considerations for treatment selection at first relapseNursing implications and supportive care considerations for patients receiving therapy for relapsed diseasePresenter:Charise Gleason, MSN, NP-BC, AOCNPAdvanced Practice

en

00:12:22

Caring for Patients With Newly Diagnosed Multiple...

Decera Clinical Education Oncology Podcast ·

2021/07/14

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include:IMWG criteria for diagnosing smoldering and active myelomaRisk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS stagingIndividualizing initial treatment for ASCT-ineligible myelomaSelecting optimal initial treatment for

en

00:07:35

Precision Medicine in Gynecologic Cancers: Expert...

Decera Clinical Education Oncology Podcast ·

2021/07/12

In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including: Adding bevacizumab to chemotherapy in frontline endometrial cancerLenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancerPARP inhibitor maintenance in ovarian cancerBevacizumab with or without PARP inhibitors in ovarian

en

00:13:35

Expert Answers to Questions on Managing...

Decera Clinical Education Oncology Podcast ·

2021/07/12

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including: Whole exome sequencing for diagnosisWhen to treat asymptomatic tumorsGenetic testing of family membersChoosing a MEK inhibitorSupportive care for acneiform rashOther RAS pathway inhibitorsPresenters:Scott R. Plotkin, MD, PhDExecutive DirectorPappas Center for Neuro-OncologyProfessor of NeurologyHarvard Medical

en

00:07:23

Expert Answers to Questions on PARP Inhibitor...

Decera Clinical Education Oncology Podcast ·

2021/06/30

In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including: Germline and somatic mutation testingPARP inhibition in earlier stage diseasePARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapyPARP inhibition in taxane-sensitive patientsPresenters:Wassim Abida, MD, PhDAssistant MemberAssistant Attending

en

00:11:37

Immunotherapy for Advanced HCC: Current Options and...

Decera Clinical Education Oncology Podcast ·

2021/06/29

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:Current systemic therapy standards of care for patients with advanced HCCUse of single-agent immune checkpoint inhibitor therapy in the first-line settingAssessing bleeding riskUsing immunotherapy in patients with active HBV or HCV infectionsPresenters:David Kaplan, MD, MScAssociate

en

224 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College